Maternal Serum Stathmin-1 Levels in Preeclampsia

A Comparative Study of Maternal Serum Stathmin-1 Levels in Pregnancies With Preeclampsia, Severe Preeclampsia, and Healthy Controls

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06623955

Enrollment

Registered

2024-10-02

Start date

2023-01-01

Completion date

2024-03-01

Last updated

2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Eclampsia

Brief summary

This study investigates maternal serum Stathmin-1 (STMN-1) levels in pregnancies complicated by preeclampsia and severe preeclampsia, compared to healthy pregnancies. The aim is to explore potential differences in STMN-1 levels among these groups to better understand its role in preeclampsia pathophysiology. Maternal serum STMN-1 levels will be measured between 32-34 weeks of gestation, and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of Preeclampsia: Defined by New-onset hypertension (Systolic Blood Pressure ≥140 mmHg and/or Diastolic Blood Pressure ≥90 mmHg) after 20 weeks of gestation, with or without proteinuria. * Clinical diagnosis of Severe Preeclampsia: Defined by criteria such as severe hypertension (systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg), organ dysfunction (renal insufficiency, liver involvement, neurological complications), thrombocytopenia, pulmonary edema, or fetal growth restriction. * Control Group: Healthy pregnancies without preeclampsia

Exclusion criteria

* Multiple Pregnancies * Pregestational Diabetes * Chronic Hypertension * Systemic Diseases (Chronic kidney disease, autoimmune diseases) * Fetal Anomalies * Premature Rupture of Membranes

Design outcomes

Primary

Measure	Time frame	Description
Maternal Serum Stathmin-1	Up to 8 weeks (Patients will be followed from inclusion in the study until the end of their pregnancy.)	To compare Stathmin-1 Levels between the pre-eclampsia and the control group.

Countries

Turkey (Türkiye)

Outcome results